Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease
Identifieur interne : 002672 ( Main/Exploration ); précédent : 002671; suivant : 002673Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease
Auteurs : A J Lees [Royaume-Uni] ; V. Ratziu [France] ; E. Tolosa [Espagne] ; W H Oertel [Allemagne]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2007-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- AEs, adverse events, ALT, alanine aminotransferase, AST, aspartate aminotransferase, COMT, catechol-O-methyltransferase, Human, Nervous system diseases, PD, Parkinson’s disease, Parkinson disease, Parkinson’s disease, Safety, Tolcapone, Treatment, ULN, upper limit of normal, UPDRS, Unified Parkinson’s Disease Rating Scale, adverse events, hepatoxicity, levodopa, liver transaminases, tolcapone.
Abstract
Objective: The safety and tolerability of adjunctive tolcapone initiated simultaneously with levodopa was evaluated with a focus on increases in liver transaminase and hepatotoxicity. Methods: 677 levodopa-naïve patients with early stage Parkinson’s disease (PD) were randomised to receive placebo or tolcapone 100 mg three times daily, added to standard doses of levodopa plus carbidopa or benserazide. Results: Increases in liver transaminase above the upper limit of normal (ULN) occurred in 69/342 (20.2%) and 92/335 (27.5%) patients in the placebo and tolcapone groups, respectively. Increases ⩾3 times the ULN occurred in 4/342 (1.2%) and 6/335 (1.8%) patients receiving placebo and tolcapone, respectively (p = 0.5). Liver transaminase values returned to normal in 65% of placebo and 80% of tolcapone treated patients. No instances of serious hepatotoxicity were seen. Diarrhoea was the most commonly reported AE—36/342 (11.0%) placebo v 98/335 (29.0%) tolcapone—and caused discontinuation in 9.9% of tolcapone treated patients. Overall, study discontinuation due to adverse effects was 2.9% in the placebo group and 17.3% in the tolcapone group. Conclusions: Tolcapone seemed to be safe and was generally well tolerated as an adjunctive treatment in patients starting treatment with carbidopa/levodopa for symptomatic PD. Mild increases in transaminase levels—<3 times the ULN—occurred commonly in both placebo and tolcapone treated patients, whereas potentially serious increases of up to ⩾3 times the ULN were infrequent.
Url:
- https://api.istex.fr/document/6DE29BEE87940A31FC2E1846BC5C3A12EB29AADC/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117861
DOI: 10.1136/jnnp.2006.097154
Affiliations:
- Allemagne, Espagne, France, Royaume-Uni
- Angleterre, Catalogne, District de Giessen, Grand Londres, Hesse (Land), Île-de-France
- Barcelone, Londres, Marbourg, Paris
- University College de Londres, Université Pierre-et-Marie-Curie, Université de Barcelone
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002095
- to stream Istex, to step Curation: 002093
- to stream Istex, to step Checkpoint: 000868
- to stream Pmc, to step Corpus: 000299
- to stream Pmc, to step Curation: 000297
- to stream Pmc, to step Checkpoint: 000889
- to stream Ncbi, to step Merge: 000671
- to stream Ncbi, to step Curation: 000671
- to stream Ncbi, to step Checkpoint: 000671
- to stream Main, to step Merge: 002937
- to stream PascalFrancis, to step Corpus: 000A18
- to stream PascalFrancis, to step Curation: 000A15
- to stream PascalFrancis, to step Checkpoint: 000855
- to stream Main, to step Merge: 002A68
- to stream Main, to step Curation: 002672
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease</title><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></author><author><name sortKey="Ratziu, V" sort="Ratziu, V" uniqKey="Ratziu V" first="V" last="Ratziu">V. Ratziu</name></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E" last="Tolosa">E. Tolosa</name></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6DE29BEE87940A31FC2E1846BC5C3A12EB29AADC</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1136/jnnp.2006.097154</idno><idno type="url">https://api.istex.fr/document/6DE29BEE87940A31FC2E1846BC5C3A12EB29AADC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002095</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002095</idno><idno type="wicri:Area/Istex/Curation">002093</idno><idno type="wicri:Area/Istex/Checkpoint">000868</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000868</idno><idno type="wicri:doubleKey">0022-3050:2007:Lees A:safety:and:tolerability</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117861</idno><idno type="RBID">PMC:2117861</idno><idno type="wicri:Area/Pmc/Corpus">000299</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000299</idno><idno type="wicri:Area/Pmc/Curation">000297</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000297</idno><idno type="wicri:Area/Pmc/Checkpoint">000889</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000889</idno><idno type="wicri:Area/Ncbi/Merge">000671</idno><idno type="wicri:Area/Ncbi/Curation">000671</idno><idno type="wicri:Area/Ncbi/Checkpoint">000671</idno><idno type="wicri:doubleKey">0022-3050:2006:Lees A:safety:and:tolerability</idno><idno type="wicri:Area/Main/Merge">002937</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0382769</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A18</idno><idno type="wicri:Area/PascalFrancis/Curation">000A15</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000855</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000855</idno><idno type="wicri:doubleKey">0022-3050:2007:Lees A:safety:and:tolerability</idno><idno type="wicri:Area/Main/Merge">002A68</idno><idno type="wicri:Area/Main/Curation">002672</idno><idno type="wicri:Area/Main/Exploration">002672</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease</title><author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Ratziu, V" sort="Ratziu, V" uniqKey="Ratziu V" first="V" last="Ratziu">V. Ratziu</name><affiliation wicri:level="4"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E" last="Tolosa">E. Tolosa</name><affiliation wicri:level="4"><country xml:lang="fr">Espagne</country><wicri:regionArea>Servicio Neurologia, Hospital Clinic Universitat de Barcelona, IDIBAPS, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName><orgName type="university">Université de Barcelone</orgName></affiliation></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Philipps-Universitat, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2007-09">2007-09</date><biblScope unit="volume">78</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="944">944</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">6DE29BEE87940A31FC2E1846BC5C3A12EB29AADC</idno><idno type="DOI">10.1136/jnnp.2006.097154</idno><idno type="href">jnnp-78-944.pdf</idno><idno type="PMID">17098835</idno><idno type="local">0780944</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AEs, adverse events</term><term>ALT, alanine aminotransferase</term><term>AST, aspartate aminotransferase</term><term>COMT, catechol-O-methyltransferase</term><term>Human</term><term>Nervous system diseases</term><term>PD, Parkinson’s disease</term><term>Parkinson disease</term><term>Parkinson’s disease</term><term>Safety</term><term>Tolcapone</term><term>Treatment</term><term>ULN, upper limit of normal</term><term>UPDRS, Unified Parkinson’s Disease Rating Scale</term><term>adverse events</term><term>hepatoxicity</term><term>levodopa</term><term>liver transaminases</term><term>tolcapone</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Sécurité</term><term>Tolcapone</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: The safety and tolerability of adjunctive tolcapone initiated simultaneously with levodopa was evaluated with a focus on increases in liver transaminase and hepatotoxicity. Methods: 677 levodopa-naïve patients with early stage Parkinson’s disease (PD) were randomised to receive placebo or tolcapone 100 mg three times daily, added to standard doses of levodopa plus carbidopa or benserazide. Results: Increases in liver transaminase above the upper limit of normal (ULN) occurred in 69/342 (20.2%) and 92/335 (27.5%) patients in the placebo and tolcapone groups, respectively. Increases ⩾3 times the ULN occurred in 4/342 (1.2%) and 6/335 (1.8%) patients receiving placebo and tolcapone, respectively (p = 0.5). Liver transaminase values returned to normal in 65% of placebo and 80% of tolcapone treated patients. No instances of serious hepatotoxicity were seen. Diarrhoea was the most commonly reported AE—36/342 (11.0%) placebo v 98/335 (29.0%) tolcapone—and caused discontinuation in 9.9% of tolcapone treated patients. Overall, study discontinuation due to adverse effects was 2.9% in the placebo group and 17.3% in the tolcapone group. Conclusions: Tolcapone seemed to be safe and was generally well tolerated as an adjunctive treatment in patients starting treatment with carbidopa/levodopa for symptomatic PD. Mild increases in transaminase levels—<3 times the ULN—occurred commonly in both placebo and tolcapone treated patients, whereas potentially serious increases of up to ⩾3 times the ULN were infrequent.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Espagne</li><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Catalogne</li><li>District de Giessen</li><li>Grand Londres</li><li>Hesse (Land)</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Londres</li><li>Marbourg</li><li>Paris</li></settlement><orgName><li>University College de Londres</li><li>Université Pierre-et-Marie-Curie</li><li>Université de Barcelone</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A J" last="Lees">A J Lees</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Ratziu, V" sort="Ratziu, V" uniqKey="Ratziu V" first="V" last="Ratziu">V. Ratziu</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E" last="Tolosa">E. Tolosa</name></region></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W H" last="Oertel">W H Oertel</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002672 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002672 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6DE29BEE87940A31FC2E1846BC5C3A12EB29AADC
|texte= Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease
}}
| This area was generated with Dilib version V0.6.29. |  |